A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis-Reference-Cited by-同舟云学术

A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis

Published:2014-07-16 Issue:12 Volume:28 Page:2304-2310
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Venner C P,Gillmore J D,Sachchithanantham S,Mahmood S,Lane T,Foard D,Rannigan L,Gibbs S D J,Pinney J H,Whelan C J,Lachmann H J,Hawkins P N,Wechalekar A D

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2014218.pdf

Reference42 articles.

1. Perfetti V, Vignarelli MC, Casarini S, Ascari E, Merlini G . Biological features of the clone involved in primary amyloidosis (AL). Leukemia 2001; 15: 195–202.

2. Wechalekar AD, Schonland SO, Kastritis E, Gillmore JD, Dimopoulos MA, Lane T et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood 2013; 121: 3420–3427.

3. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012; 30: 989–995.

4. Dispenzieri A, Gertz MA, Kumar SK, Lacy MQ, Kyle RA et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2004; 104: 1881–1887.

5. Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997; 336: 1202–1207.

Cited by 86 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. AL amyloidosis: Singapore Myeloma Study Group consensus guidelines on diagnosis, treatment and management;Annals of the Academy of Medicine, Singapore;2023-11-29

2. Long-term prognosis of AL amyloidosis in patients treated with bortezomib or thalidomide;2023-01-18

3. Treatment of AL Amyloidosis;Amyloidosis and Fabry Disease;2023

4. Daratumumab in AL amyloidosis;Blood;2022-12-01

5. Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis;Blood Advances;2022-09-23